611 related articles for article (PubMed ID: 9725776)
1. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing serum aluminum in CAPD patients.
Montenegro J; Aguirre R; Saracho R; Moina I; Martínez I
Clin Nephrol; 1998 Aug; 50(2):77-83. PubMed ID: 9725777
[TBL] [Abstract][Full Text] [Related]
3. Competition of iron and aluminum for transferrin: the molecular basis for aluminum deposition in iron-overloaded dialysis patients?
Van Landeghem GF; D'Haese PC; Lamberts LV; De Broe ME
Exp Nephrol; 1997; 5(3):239-45. PubMed ID: 9208284
[TBL] [Abstract][Full Text] [Related]
4. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
8. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
[TBL] [Abstract][Full Text] [Related]
9. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
Seifert A; von Herrath D; Schaefer K
Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
[TBL] [Abstract][Full Text] [Related]
10. Intravenous iron supplementation in children on hemodialysis.
Leijn E; Monnens LA; Cornelissen EA
J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
[TBL] [Abstract][Full Text] [Related]
11. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
12. The effect of iron stores on corrected QT dispersion in patients undergoing peritoneal dialysis.
Wu VC; Huang JW; Wu MS; Chin CY; Chiang FT; Liu YB; Wu KD
Am J Kidney Dis; 2004 Oct; 44(4):720-8. PubMed ID: 15384024
[TBL] [Abstract][Full Text] [Related]
13. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
14. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
15. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
16. Serum ferritin and tissue iron in anemic dialysis patients.
Bárány P; Eriksson LC; Hultcrantz R; Pettersson E; Bergström J
Miner Electrolyte Metab; 1997; 23(3-6):273-6. PubMed ID: 9387132
[TBL] [Abstract][Full Text] [Related]
17. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
Nakazawa R
Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
[TBL] [Abstract][Full Text] [Related]
18. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
von Bonsdorff M; Sipilä R; Pitkänen E
Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
[TBL] [Abstract][Full Text] [Related]
19. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Joffe P; Olsen F; Heaf JG; Gammelgaard B; Pödenphant J
Clin Nephrol; 1989 Sep; 32(3):133-8. PubMed ID: 2791364
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a toxic effect of aluminum on osteoblasts: a histomorphometric study in hemodialysis patients with aplastic bone disease.
Parisien M; Charhon SA; Arlot M; Mainetti E; Chavassieux P; Chapuy MC; Meunier PJ
J Bone Miner Res; 1988 Jun; 3(3):259-67. PubMed ID: 3213621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
